Pushkal Garg, EVP Chief R&D at ALNYLAM PHARMACEUTICALS, INC. (ALNY), sold 5,374 shares at $461.01 ($2.5M) on 2025-08-19, disclosed to the SEC on 2025-08-19.
Scheduled sale ($2.5M) by EVP Chief R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $447.98 | 39 | $17K | 0.7% |
| 2 | $449.92 | 90 | $40K | 1.7% |
| 3 | $450.92 | 39 | $18K | 0.7% |
| 4 | $451.99 | 103 | $47K | 1.9% |
| 5 | $452.96 | 329 | $149K | 6.1% |
| 6 | $452.96 | 329 |
| $149K |
| 6.1% |
| 7 | $454.04 | 543 | $247K | 10.1% |
| 8 | $454.04 | 543 | $247K | 10.1% |
| 9 | $454.84 | 241 | $110K | 4.5% |
| 10 | $454.84 | 241 | $110K | 4.5% |
| 11 | $455.82 | 12 | $5K | 0.2% |
| 12 | $455.41 | 276 | $126K | 5.1% |
| 13 | $455.41 | 276 | $126K | 5.1% |
| 14 | $457.26 | 338 | $155K | 6.3% |
| 15 | $457.26 | 338 | $155K | 6.3% |
| 16 | $458.27 | 231 | $106K | 4.3% |
| 17 | $458.27 | 231 | $106K | 4.3% |
| 18 | $459.59 | 260 | $119K | 4.9% |
| 19 | $459.59 | 260 | $119K | 4.9% |
| 20 | $461.01 | 305 | $141K | 5.7% |
| 21 | $461.01 | 305 | $141K | 5.7% |
| 22 | $461.74 | 45 | $21K | 0.8% |
| Total | $456.11 avg | 5,374 | $2.5M | 100% |
| Filing → |
| ALNY | SELL | 2026-03-02 | $1.5M | — | Filing → |
| ALNY | SELL | 2026-02-17 | $695K | — | Filing → |
| ALNY | SELL | 2026-01-14 | $548K | — | Filing → |